General MedicationsTABLETGeneric

BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Standard Dose

200MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 218766 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Form and strength TABLET - 200MG Sponsor CIPLA LTD Submission history Latest submission status date: 2025-10-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 218766 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Form and strength TABLET - 200MG Sponsor CIPLA LTD Submission history Latest submission status date: 2025-10-14 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.